COHCAP -3+ Group Workflows
Average by CpG Site: Table of way ANOVA is used; otherwise, 1-way ANOVA is used). False discovery rate (FDR) values then calculated using the method of Benjamini and Hochberg [45] . CpG sites are then filtered based upon pvalue and FDR, and beta values are then averaged among all samples within a group for a given CpG site. CpG islands (as defined by the annotation file, which also defines the mapping between CpG islands and genes) are considered for statistical analysis if they possess a minimum number of filtered CpG sites (default = 4). CpG site p-values are calculated via ANOVA F-statistic for averaged beta values (using a 2-way ANOVA considering the influence of group and CpG site pairs on beta value variation). FDR values then calculated using the method of Benjamini and Hochberg [45] . Integration with gene expression data is not possible with this workflow. Table of 
Average by CpG Island (recommended):

Sample Processing
When raw Illumina 450k methylation data was available, the data was normalized in Illumina® Genome Studio TM (V2011.1) using a background correction normalized to Illumina controls (without providing any grouping information -each sample was identified as a separate group for normalization purposes Raw BS-Seq data [36] was aligned using Bismark [43] , and sites with at least 10x coverage were included in the .bed files used in for COHCAP analysis.
The novel methylation and gene expression data presented in this study can be downloaded from GEO (GEO SuperSeries GSE42310; expression in GSE42307, HCT116 methylation in GSE42308, HES--2 450k methylation in GSE42707, and HES--2 MIRA methylation in GSE42734).
HCT116 Dataset and Validation of Differential Methylation
Gene expression analysis was performed using RNA extracted with the RNeasy kit (Qiagen) from HCT116 human colon cancer cell lines. The microarray sample preparation was carried out using Ambion's WT Expression kit (Life Technologies, Carlsbad, CA) and Affymetrix's GeneChip Terminal labeling system at the COH Functional Genomics Core using a procedure described previously [57] .
Briefly, 100 ng of total RNA was used to start the first strand cDNA synthesis using random primers plus polyT7 promoter. The RNA quality was checked using Agilent Bioanalzer nano 6000 and all RNA had a RIN > 9 for this study before the 1 st stand synthesis. After the 2 nd strand cDNA synthesis, the antisense cRNA was carried using T7 RNA polymerase. Then, 10 µg of cRNA was used to start the 2nd cycle of cDNA synthesis using random primers plus dUTP and dNTP mix. The single-strand cDNA was fragmented and then end-labeled with biotinylated nucleotides in the presence of terminal deoxynucleotidyl transferase (TdT) using Affymetrix WT Terminal Labeling kit. Five µg of labeled single stranded cDNA was hybridized with Affymetrix Human Gene 1.0 ST arrays the arrays were scanned using Affymetrix GeneChip Scanner 3000 7G.
Genomic DNA was prepared from HCT116 human colon cancer cell lines using the DNeasy Tissue kit following manufacturer's instructions (Qiagen). DNA was extracted from HCT116 human colon cancer cell lines using Qiagen kit. Illumina MethylHuman450k beadchip methylation analysis was performed following Illumina Infinium HD methylation assay protocol at the COH Functional Genomics
Core. Briefly, 500 ng high quality genomic DNA of each sample was treated with Zymo EZ DNA methylation kit (Zymo Research) to convert unmethylated cytosines to uracil, while leaving methylated cytosines unchanged for methylation analysis. The bisulfate-converted DNA was denatured with 0.1 N NaOH and amplified at 37°C for 20-24 hours. After fragmentation, the amplified DNA was precipitated with 2-propanol. The DNA was resuspended in 46 µl RA1 buffer and 15 µl resuspended DNA was loaded 6 into each beadchip section. The beadchip was assembled into the Hyb chamber and incubated in a 48°C degree in Illumina hybridization oven for at least 16 hours. After washing, the beadchip was assembled into a flow-through chamber and single base extension and staining was performed at 44°C on the chamber rack. After washing, the stained beadchip was coated with XC4 buffer and scanned using Illumina's HiScanSQ scanner.
Validation of gene expression levels was determined by real-time RT-PCR. Briefly, total RNA was reverse transcribed to cDNA using iScript cDNA Synthesis Kit (Bio-Rad), and real-time RT-PCR reactions were performed using iQ SYBR Green supermix (Bio-Rad) on a DNA Engine thermal cycler equipped with Chromo4 detector (Bio-Rad). Gene specific primer sets were purchased from RealTimePrimers.
EpiTect MethylPCR assay (Qiagen) was performed to validate DNA methylation levels.
Unmethylated or methylated DNA was selectively digested by methylation-sensitive (cuts unmethylated and partially methylated DNA, leaving only hypomethylated DNA) and methylation-dependent restriction enzymes (cuts any methylated DNA, leaving only unmethylated DNA) according to the manufacturer's instructions. The remaining DNA after digestion was quantified by real-time PCR using primers detecting methylation status of the CpG islands associated with the individual gene. The relative concentrations of differentially methylated DNA were determined by comparing the amount of each digest with that of mock digest (no enzyme added), using the software provided by the manufacturer (Qiagen). In all cases, validation was performed in triplicate.
MIRA Analysis Comparison
HES-2 cell line DNA was prepared as described in Tompkins et al. [58] , and the microarray sample was processed at the UCLA DNA Microarray Core. The data for the MIRA sample (GSE42734) was processed using NimbleScan (v 2.6.0.0) to compute ratio files and find peaks (sliding window width = 750 bp, mimimum -log 10 p-value cutoff = 2.0, maximum spacing between nearby probes within peak = 500 bp, minimum probes per peak = 2). The NimbleGen MeDIP array (Human DNA Methylation 3 x 720K
CpG Island Plus RefSeq Promoter Array) used for the MIRA assay defined genome coordinates based 7 upon hg18 (while the UCSC CpG islands are defined based upon hg19 coordinates), so the MIRA peaks were converted to hg19 coordinates (with a minimum re-mapping ratio of 0.95 without multiple output regions) using the lift-over function in . Likewise, the probe annotation file was converted to hg19 coordinates in the same way. Finally, peaks were annotated with UCSC CpG Islands showing at least 50% overlap (with either the peak or the island, including the 2 kb flanking region for the CpG island shores). The same DNA sample was used for the Illumina 450k array (GSE42707), which was processed in the same way as the HCT116 sample at the COH Functional Genomics Core. Integrate with Gene Expression Data (Fold--Change, P--Value, and FDR Cutoffs) [project_name] All overlap is defined based upon gene annotation. It is possible for a gene to show a negative correlation without meeting the criteria for differential methylation because the 
IMA (TSS1500) COHCAP
Blue boxes represent CpG island annotations (in this paper, these are the UCSC CpG islands). Circles represent CpG sites (red for increased methylation, green for decreased methylation). Boxes between sites represent CpG island behavior (red for increased methylation, green for decreased methylation, and grey for unchanged methylation). Notice that a single promoter can contain multiple CpG islands and some CpG islands are not necessarily located upstream of the transcription start site (TSS). IMA also provides CpG island analysis but does not provide gene mappings. Also, IMA segregates the UCSC CpG islands into 5 regions (ISLAND, NSHORE, SSHORE, NSHELF, SSHELF), whereas COHCAP considers all of these regions to be a single functional unit . This is why the cluster of down-regulated CpG sites causes the 2 nd CpG island to be considered up-regulated (e.g. the sites in the north shore are considered in the calculation of activity for the island). Density plots were created using COHCAP with 3 thresholds: 1) methylated / unmethylated threshold + FDR (orange lines), 2) FDR alone (green lines), and 3) no threshold (purple lines). Note that the correlation coefficient has to be quite strong to be detected in a small dataset but large patient cohorts can detect much more subtle correlations using the same criteria (and correlations tend to be weaker overall).
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Figure S13: COHCAP Selects Regions Enriched for Negative Correlations
This scatter plot was created using COHCAP with 3 thresholds: 1) methylated / unmethylated threshold + FDR, 2) FDR alone, and 3) no threshold. Negative correlations are shown in red, positive correlations are shown in black, and non-significant correlations are shown in grey. chr2:17721537--17722021 7 0 3.7e--15 7.8e--13 "#Methyl" and "# Unmethyl" describe the number of CpG shows showing relative hyper-- or hypo--methylation (respectively) between the mutant and parental HCT116 strains. Although two regions are listed for RAB34, they both corresponded to nearby UCSC CpG islands (with a single optimized coordinate of chr17:27,440,000--27,045,500). Likewise, validation for NEDD4L used an optimized coordinate of chr18:55,862,550--55,862,900 and TCF7L2 used the optimized coordinate of chr10:114,712,000--114,713,500. Visual inspection of the VSNL1 CpG island indicated that the original UCSC coordinates were sufficient. In general, visual inspection is necessary because the CpG shores are included in the CpG island mappings and the overall range will not provide the most precise location of the differentially methylated CpG sites. Genome coordinates are specified with respect to hg19. NA NA CpG site analysis is identical for either workflow, but site counts vary because the "Average by Island" workflow includes a minimum number of sites per island in this early filtering step (but this is not considered until the integration step for the "Average by Site" workflow). "Patient IDs" means 2--way ANOVA takes tumor vs. normal patient pairing consideration. "Paired" means only samples with paired tumor and normal data were included (N=134). "All" means all possible samples were included (N=562). Analysis was performed with methylated / unmethylated beta values = 0.3; p--value cutoff = FDR cutoff = 0.05; Minimum number of sites per island= 4; fold--change cutoff=1.5; correlation coefficient cutoff = --0.2. Although the sample size varies by ~4x, the number of regions identified is very similar with paired vs. all samples. SFRP1 Increase (0.19) Prognosis TSS1500 (0.026) *Only TSS200, TSS1500, EXON1, and GENEBODY IMA regions have mappings to genes are considered in the "Identified with IMA?" column. Delta beta values are shown in parentheses (to check concordance of methylation change). Genes with similar trends are shown in bold. IGFBP3 and GSTM2 are shown in red because they are the only genes with roughly corresponding magnitude of change and location of CpG Island. for TSS1500 regions are considered for this analysis, and delta beta values are shown in parentheses. IMA identified 33 biomarkers with decreased methylation and increased expression and 22 biomarkers with increased methylation and decreased expression. The subset of genes associated with disease progression and prognosis (instead of disease progression, diagnosis, efficacy, prognosis, or response to therapy) are shown in the table above. A total of 2039 genes (2.7% known biomarkers) were considered for IMA biomarker analysis while 247 genes were considered for COHCAP biomarker analysis (4.9% known biomarkers). 
Figure S21: Decreased Methylation at the ESR1 TSS in Breast Tumors
